South Dakota Investment Council Acquires 9,529 Shares of IQVIA Holdings Inc. $IQV

South Dakota Investment Council raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,241 shares of the medical research company’s stock after buying an additional 9,529 shares during the period. South Dakota Investment Council’s holdings in IQVIA were worth $18,470,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. CI Investments Inc. raised its stake in IQVIA by 2.1% in the 3rd quarter. CI Investments Inc. now owns 121,562 shares of the medical research company’s stock valued at $23,089,000 after acquiring an additional 2,520 shares during the period. Strive Asset Management LLC acquired a new position in shares of IQVIA in the third quarter valued at $17,447,000. Focus Partners Advisor Solutions LLC raised its position in shares of IQVIA by 9.4% in the third quarter. Focus Partners Advisor Solutions LLC now owns 6,184 shares of the medical research company’s stock valued at $1,251,000 after purchasing an additional 530 shares during the period. Elo Mutual Pension Insurance Co lifted its stake in shares of IQVIA by 97.1% during the 3rd quarter. Elo Mutual Pension Insurance Co now owns 29,160 shares of the medical research company’s stock worth $5,539,000 after buying an additional 14,362 shares during the last quarter. Finally, APG Asset Management N.V. boosted its holdings in shares of IQVIA by 1.5% during the 3rd quarter. APG Asset Management N.V. now owns 102,239 shares of the medical research company’s stock worth $19,419,000 after buying an additional 1,500 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $174.48 on Tuesday. The firm has a market cap of $29.61 billion, a PE ratio of 22.20, a price-to-earnings-growth ratio of 1.72 and a beta of 1.40. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The stock’s fifty day moving average price is $211.19 and its two-hundred day moving average price is $208.02. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on IQV. Citigroup lowered their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Barclays lowered their target price on IQVIA from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Friday, February 6th. UBS Group reduced their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Jefferies Financial Group decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, TD Cowen lifted their target price on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.